Glioblastoma Clinical Trial
Official title:
Phase II Study of Dose Intensive Temozolomide in Elderly Adults With Newly Diagnosed Glioblastoma
A single arm Phase 2 trial with the study drug temozolomide (temodar) for newly diagnosed
glioblastoma in elderly patients (defined as greater than or equal to 70 years old).
Following surgical resection, and confirmation of glioblastoma, patients will proceed to
primary chemotherapy with temozolomide (temodar). Temodar is given for 42 consecutive days
on and 14 days off occurring every 56 days.
Procedures prior to initial study treatment (<14 Days) are: Neurological/Oncological
History, Neurological Examination, Height, Weight, and Body Surface Area, Performance
Status, Quality Of Life FACT-BR, Labs, MGMT tissue analysis, and Cranial CT/MRI with and
without contrast.
The same procedures are repeated on Day 1 of each treatment cycle with the addition of an
adverse event assessment. And the off study procedures for patients are performance status,
Quality Of Life FACT-BR, MGMT tissue analysis, and cranial CT/MRI with and without contrast.
Patients may continue with each temodar daily dose therapy if clinical and
neuroradiographical exams are stable or improving.
A single arm Phase 2 trial with the study drug temozolomide (temodar) for newly diagnosed
glioblastoma in elderly patients (defined as greater than or equal to 70 years old).
Temozolomide will be administered orally (a capsule) at approximately the same time daily
(bedtime) for 42 days on and then 14 days off; cycles may be repeated every 56 days.
Complete blood counts will be obtained bi-weekly, evaluations monthly and MRI's every 2
months after a cycle of therapy.
Procedures prior to initial study treatment (<14 Days) are: Neurological/Oncological
History, Neurological Examination, Height, Weight, and Body Surface Area, Performance
Status, Quality Of Life FACT-BR, Labs, MGMT tissue analysis, and Cranial CT/MRI with and
without contrast (all disease found at staging must be followed using the same modality used
at Pre-treatment. Tumor assessments are to be repeated every 56 days thereafter until
progression). The same procedures are repeated on Day 1 of each treatment cycle with the
addition of an adverse event assessment.
Patients may continue on therapy unless one of the following occurs:
- Documented or clinical progressive disease at any time
- Unacceptable toxicity
- Treatment delay of > 2 weeks for any reason
- Study data or other data indicate that the study treatment is not beneficial for the
patients; defined as at least one response in the first 12 patients within each tumor
histology strata
- Non-compliance by the patient with protocol requirements (follow-up, treatment,
administration of disallowed therapy)
- Changes in medical status of the patient such that the patient no longer meets
eligibility requirements (leptomeningeal spread, change in mental competency) or the
investigator believes that patient safety will be compromised.
- Patient withdrawal of consent for treatment
- Occurrence of one toxic death
Patients with CR, PR, or stable disease (SD) will be treated for a minimum of 3 cycles [6
months] or until disease progression. For patients responding to treatment, continuation of
therapy beyond 3 cycles is at the discretion of the investigator. Response parameters will
include the MacDonald criteria for evaluating brain tumors. Response is measured by a
reduction in tumor size.
After cessation of protocol therapy, patients will continue to be followed for survival at
2-month intervals for up to three years from start of treatment. And the off study
procedures for patients are performance status, Quality Of Life FACT-BR, MGMT tissue
analysis, and cranial CT/MRI with and without contrast.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05664243 -
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
Recruiting |
NCT05635734 -
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT03679754 -
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
|
Phase 1 | |
Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
Terminated |
NCT03927222 -
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
|
Phase 2 | |
Recruiting |
NCT03897491 -
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT03587038 -
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
|
Phase 1 | |
Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
Recruiting |
NCT04391062 -
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT03661723 -
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT02655601 -
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
|
Phase 2 | |
Completed |
NCT02206230 -
Trial of Hypofractionated Radiation Therapy for Glioblastoma
|
Phase 2 | |
Completed |
NCT03493932 -
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
|
Phase 1 | |
Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT03018288 -
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
|
Phase 2 | |
Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
Not yet recruiting |
NCT04552977 -
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
|
Phase 2 | |
Terminated |
NCT02905643 -
Discerning Pseudoprogression vs True Tumor Growth in GBMs
|